Conference Call with Glenmark Pharmaceuticals Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Glenmark Pharmaceuticals announced Q1FY26 results Consolidated revenue was Rs 32,644 million as against Rs 32,442 million, recording an increase of 0.6% YoY. EBITDA was Rs 5,805 million in Q1FY26, as compared to Rs 5,607 million in Q1FY25, with an EBITDA margin of 17.8%. Adjusted Profit After Tax (PAT) for Q1FY26 was at Rs 3,129 million, with an adjusted PAT margin of 9.6%. Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals, said: “In Q1FY26, our U.S. business delivered QoQ growth, driven by a combination of injectable and partnered products launches. Our Europe and Emerging markets businesses have recorded >25% CAGR and >10% CAGR respectively over the last three years, and we expect the region to deliver a double-digit growth from the second quarter onwards. The recent IGI-AbbVie global licensing agreement for ISB 2001 is a strong validation of our innovation capabilities. We remain confident in our strategy to drive growth across our markets, while advancing our branded, speciality, and innovative products to deliver long-term value for our stakeholders.” Result PDF